Stacy Lindborg compensation by year
BRAINSTORM CELL THERAPEUTICS Summary Compensation Table · all 5 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Salary | $218,750 | $469,000 | $469,000 | $475,000 | $125,947 |
| Bonus | $10,000 | $189,150 | $164,150 | $200,000 | $100,000 |
| Stock awards | $186,250 | $0 | $143,150 | $256,650 | $79,839 |
| Option awards | $404,358 | $0 | $0 | $0 | — |
| Non-equity incentive | $0 | $0 | $0 | $0 | — |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | — |
| All other | $48,147 | $78,530 | $75,243 | $76,075 | $40,589 |
| Total | $867,505 | $736,680 | $851,543 | $1,007,725 | $346,375 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BRAINSTORM CELL THERAPEUTICS INC. DEF 14A filed May 16, 2025, accession 0001104659-25-049785, and prior-year filings. Open the filing on EDGAR.
How this page was built: the BRAINSTORM CELL THERAPEUTICS INC. filed document, accession 0001104659-25-049785. Every figure is read from that document and cited to the page and table it appears in. Filed May 16, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 16,129 | $36,613 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in BRAINSTORM CELL THERAPEUTICS INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2024 proxy (filed May 16, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-02-26 | Grant or award derivative | — | 150,000 | $0.70 | 150,000 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
BRAINSTORM CELL THERAPEUTICS’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Chaim Lebovits | Chief Executive Officer & President | $750,303 |
| Ibrahim Dagher | Executive Vice President, Chief Medical Officer | $498,578 |
| Stacy Lindborg · this page | Former Co-Chief Executive Officer | $346,375 |
| Uri Yablonka | Executive Vice President, Chief Business Officer, Secretary and Director | $266,138 |
Board service
BRAINSTORM CELL THERAPEUTICS board · FY2024How this board is paid
Company policy: BRAINSTORM CELL THERAPEUTICS pays directors a $0 cash retainer. As stated in BRAINSTORM CELL THERAPEUTICS's FY2024 proxy.
The full BRAINSTORM CELL THERAPEUTICS compensation record
free company briefThis page is one person within BRAINSTORM CELL THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BRAINSTORM CELL THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.